Tempus AI's stock surged 5.04% during intraday trading following the announcement of positive results from its ALERT trial in collaboration with Medtronic.

The study, which was presented at the American College of Cardiology's 75th Annual Scientific Session, met its primary endpoint, demonstrating that automated AI-driven notifications in electronic health records were superior to usual care in a win ratio analysis. The trial specifically showed that these AI EHR alerts improved timely evaluation and treatment for patients with significant aortic stenosis or mitral regurgitation.

Further details from the trial indicated that the EHR-integrated decision support could help narrow undertreatment disparities by standardizing follow-up for high-risk findings across different patient groups. One report highlighted that the AI alerts lifted valve interventions by 40%, representing a significant improvement in patient care outcomes.